Virus

EQS-News: G.ST Antivirals reports start of Phase II trial and announces appointment of Ronald Bruce Turner as new Chief Medical Officer

Retrieved on: 
Wednesday, April 10, 2024

An expert in the clinical research of respiratory viruses, Dr. Turner will oversee the Company’s current clinical trial and drive further clinical development.

Key Points: 
  • An expert in the clinical research of respiratory viruses, Dr. Turner will oversee the Company’s current clinical trial and drive further clinical development.
  • This study aims to assess the effectiveness of 2-DG in preventing illness from rhinoviruses, reducing infection rates, and easing symptom severity.
  • A total of 128 volunteers will participate, receiving up to four daily intranasal doses of either 2-DG or a placebo.
  • 2-DG is a unique and intriguing therapeutic approach to treating viral infections by blocking the virus’ nutrient access,” commented Ronald Bruce Turner, MD, CMO of G.ST Antivirals.

GERMAGIC(TM) PET Hosts "Social Inclusion Charity Run with Pets"

Retrieved on: 
Monday, March 18, 2024

GERMAGIC(TM) PET is the title sponsor of the "Social Inclusion Charity Run with Pets" on 17 March.

Key Points: 
  • GERMAGIC(TM) PET is the title sponsor of the "Social Inclusion Charity Run with Pets" on 17 March.
  • To provide pets with more care and protection, GERMAGIC(TM) PET continuously innovates and utilizes its scientific research technology to develop various green pet health products, thus promoting social inclusion and sustainable development.
  • GERMAGIC(TM) PET products utilize GERMAGIC(TM)'s encapsulation technology and molecular materials to comprehensively support and protect pet health.
  • This certification not only recognizes the quality of GERMAGIC(TM) PET products but also sets higher quality standards for the pet health industry.

Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives

Retrieved on: 
Thursday, April 4, 2024

SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.
  • “We are thrilled to have received this newly granted patent in Israel,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • Israel’s pharmaceuticals and biotechnology market has a reputation for high R&D spending and an impressive international reach, with world-class export numbers and a growing market value.
  • Other examples include influenza A, Ross River virus, and coronaviruses, including those responsible for severe acute respiratory syndrome and SARS-CoV-2 (COVID-19).

Highest Performances Announces Acquisition of an AI Humanoid Robot Hardware Manufacturer

Retrieved on: 
Thursday, March 28, 2024

Pursuant to the Supplementary Agreement II, the Company will acquire 77.5% of the equity interests in Singapore White Lingjun Pte.

Key Points: 
  • Pursuant to the Supplementary Agreement II, the Company will acquire 77.5% of the equity interests in Singapore White Lingjun Pte.
  • In exchange, the Company will issue an aggregate of 20,758,929 American Depositary Shares (“ADSs”), equivalent to 31,138,394 ordinary shares of the Company, to White Group.
  • Ltd. has been dedicated to developing and manufacturing world-class quality, affordable artificial intelligence (“AI”) Humanoid hardware products with proprietary technology since 2014.
  • Singapore Lingjun’s Al Humanoid are crafted using advanced medical procedures, such as skin texture simulation technology, to provide hyper-realistic touch and feel.

Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025

Retrieved on: 
Wednesday, March 27, 2024

Extended financial visibility secured until Q4 2025 through a revised credit facility provided by the major shareholder Institut Mérieux.

Key Points: 
  • Extended financial visibility secured until Q4 2025 through a revised credit facility provided by the major shareholder Institut Mérieux.
  • “During 2023 Transgene continued to make significant progress, delivering compelling data that confirm the value of our approach to treating cancer using our novel immunotherapies” commented Dr. Alessandro Riva, MD, Chairman and CEO of Transgene.
  • As announced on May 5, 2023, AstraZeneca terminated its oncolytic virus research and development collaboration with Transgene following a strategic review of its pipeline.
  • In 2024, Transgene expects to communicate progress and significant results and readout on all of its clinical stage assets.

Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024

Retrieved on: 
Tuesday, April 9, 2024

The poster, titled “Deciphering anticancer mechanisms of oncolytic virus-loaded stem cells,” will be presented on April 9, 2024, during the Chemotherapy, Radiation, and Vaccine Mediated Immunity session.

Key Points: 
  • The poster, titled “Deciphering anticancer mechanisms of oncolytic virus-loaded stem cells,” will be presented on April 9, 2024, during the Chemotherapy, Radiation, and Vaccine Mediated Immunity session.
  • “Calidi’s novel approach to treating cancer has always centered around the stem cell as a means of protecting, delivering, and potentiating our tumor-killing virotherapeutic payloads.
  • In the studies presented at AACR, scientists at Calidi Biotherapeutics and City of Hope researched the stem cells secretome transcriptomic of CLD-101 and CLD-201.
  • This poster will be posted to the “Scientific Publications” section of the Calidi Biotherapeutics website following the conclusion of the conference.

City of Hope Scientists Present Leading-Edge Research at American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Monday, April 8, 2024

“City of Hope’s research presented at AACR’s conference this year reinforces our focus on early detection, smarter and more precise treatments, and achieving health equity.

Key Points: 
  • “City of Hope’s research presented at AACR’s conference this year reinforces our focus on early detection, smarter and more precise treatments, and achieving health equity.
  • “Cancer is complex and the breadth and diversity of research this year further underscores the talent, scientific rigor and curiosity at City of Hope,” Van den Brink added.
  • But those diagnosed when the cancer is contained to the pancreas have a 44.3% relative survival rate after five years.
  • Scientists with Translational Genomics Research Institute, part of City of Hope, also contributed to the study.

Certain DWS Closed-End Funds Declare Monthly Distributions

Retrieved on: 
Monday, April 8, 2024

When distributions exceed total return performance, the difference will reduce a Fund’s net asset value.

Key Points: 
  • When distributions exceed total return performance, the difference will reduce a Fund’s net asset value.
  • The final determination of the source and tax status of all distributions paid in 2024 will be made after the end of 2024 and will be provided on Form 1099-DIV.
  • Although the fund seeks income that is exempt from federal income taxes, a portion of the fund’s distributions may be subject to federal, state and local taxes, including the alternative minimum tax.
  • Closed-end funds, unlike open-end funds, are not continuously offered.

LANDSEA HOMES LAUNCHES HIGH PERFORMANCE HOME PROGRAM IN COLORADO; CELEBRATES GRAND OPENINGS FOR TWO NEW COMMUNITIES

Retrieved on: 
Monday, April 8, 2024

*

Key Points: 
  • *
    The company's notable homes merge design, technology, and sustainability to promote energy savings and a healthy lifestyle.
  • Landsea Homes entered the Colorado housing market last October via the acquisition of Richfield Homes.
  • All of Landsea Homes' High Performance Homes are supported by a partnership with Apple®, the homes utilize the Apple HomeKit™ environment to operate all home automation features from one mobile application.
  • For more information about Landsea Homes' High Performance Home program, visit https://landseahomes.com/hph .

Philips GoPure GP5212 Automotive Air Purifier Removes up to 90% of Airborne Pollen Inside Vehicles

Retrieved on: 
Friday, April 5, 2024

FARMINGTON HILLS, Mich., April 5, 2024 /PRNewswire/ -- Lumileds, a leading lighting solutions company, offers the Philips GoPure GP5212 Automotive Air Purifier for those who suffer from seasonal allergies. Powerful, compact, and simple to use, GoPure GP5212 effectively filters out airborne allergens including pollen and mold that can pass through the cabin filters typically found in vehicles. Standard cabin air filters typically trap particulates of 5-100 microns. The Philips GoPure GP5212 can filter particles as small as .015 microns, including allergens, viruses, and bacteria, as well as toxic gases. The advanced filtering of the GoPure GP5212 helps trap pollen, keeping it out of the eyes and airways of vehicle occupants.

Key Points: 
  • The Philips GoPure GP5212 can filter particles as small as .015 microns, including allergens, viruses, and bacteria, as well as toxic gases.
  • The advanced filtering of the GoPure GP5212 helps trap pollen, keeping it out of the eyes and airways of vehicle occupants.
  • Phillips GoPure GP5212 car air purifier meets a growing demand for clean air solutions.
  • "The new Phillips GoPure GP5212 car air purifier meets a growing demand for clean air solutions," noted Aubry Baugh, Lumileds Sr.